PharmX Technologies（PHX）株式概要ファルクス・テクノロジーズ社（PharmX Technologies Limited）は、その子会社とともに、オーストラリアで技術およびソフトウェア開発会社として事業を展開している。 詳細PHX ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6リスク分析過去5年間で収益は年間52.7%減少しました。 Australian市場と比較した過去 3 か月間の株価の変動意味のある時価総額がありません ( A$73M )すべてのリスクチェックを見るPHX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueAU$Current PriceAU$0.11746.2% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-6m17m2016201920222025202620282031Revenue AU$4.6mEarnings AU$560.8kAdvancedSet Fair ValueView all narrativesPharmX Technologies Limited 競合他社Vection TechnologiesSymbol: ASX:VR1Market cap: AU$55.7mEtherstackSymbol: ASX:ESKMarket cap: AU$74.3mCredit ClearSymbol: ASX:CCRMarket cap: AU$111.9mIODMSymbol: ASX:IODMarket cap: AU$88.9m価格と性能株価の高値、安値、推移の概要PharmX Technologies過去の株価現在の株価AU$0.1152週高値AU$0.1752週安値AU$0.079ベータ0.321ヶ月の変化4.76%3ヶ月変化-21.43%1年変化37.50%3年間の変化168.29%5年間の変化18.28%IPOからの変化0%最新ニュースBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Jayne Shaw was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 53% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (AU$75.8m market cap, or US$55.2m).Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Jayne Shaw was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Feb 04PharmX Technologies Limited to Report First Half, 2026 Results on Feb 25, 2026PharmX Technologies Limited announced that they will report first half, 2026 results on Feb 25, 2026Board Change • Dec 24Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Jayne Shaw was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 13PharmX Technologies Limited, Annual General Meeting, Nov 11, 2025PharmX Technologies Limited, Annual General Meeting, Nov 11, 2025.最新情報をもっと見るRecent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Jayne Shaw was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 53% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (AU$75.8m market cap, or US$55.2m).Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Jayne Shaw was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Feb 04PharmX Technologies Limited to Report First Half, 2026 Results on Feb 25, 2026PharmX Technologies Limited announced that they will report first half, 2026 results on Feb 25, 2026Board Change • Dec 24Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Jayne Shaw was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 13PharmX Technologies Limited, Annual General Meeting, Nov 11, 2025PharmX Technologies Limited, Annual General Meeting, Nov 11, 2025.お知らせ • Sep 01Pharmx Technologies Limited Announces Board Changes, Effective 1 September 2025PharmX Technologies Limited announced that Mr. Alexander (Sandy) Mellis has been appointed as a full Non-Executive Director of the Company with effect from1 September 2025, having resigned from his position as an Alternate Director to Mr. Dennis Bastas. Mr. Mellis has acted as an Alternate Director to Mr. Bastas since September 2024 and has provided invaluable contribution to the Board during this time. Mr. Mellis will continue to provide his 25+ years industry experience in consumer health brands and the Australian consumer goods market across a variety of market channels to the Company, having consented to a full position on the Board. Mr. Mellis has been appointed to fill a casual vacancy in accordance with the Company's Constitution until the Company's 2025 Annual General Meeting (AGM) whereby Mr. Mellis will stand for election in accordance with the Company's Constitution and ASX Listing Rules. The Company notes it was originally intended that Mr. Mellis remain as Alternate Director until the 2025 AGM where he was then due to step down as an Alternate Director and stand for election as a Non-Executive Director, however the Board (with Mr. Mellis' endorsement) has chosen to expedite the appoint of Mr. Mellis in light of the immediate resignation of Mr. Dennis Bastas. The Company has identified and acknowledges a breach of ASX Listing Rule 14.4 in relation to Mr. Bastas' current term as a Director of the Company. At the 2024 AGM, Pharmx had planned to seek re-election of Mr. Bastas as a Non-Executive Director in accordance with the requirements under its Constitution and the ASX's Listing Rules, however due to an administrative oversight from its 2024 AGM the resolution was omitted from the Notice of Meeting, resulting in Mr. Bastas continuing as a Director for a period longer than the 3-year term stipulated by the ASX Listing Rules without standing for re- election. Mr. Bastas, by mutual agreement with the Company, has resigned as a Director of the Company with effective from 1 September 2025, allowing him to focus more fully on his position as Chairman & Group CEO of DBG Health.Board Change • Aug 23Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Jayne Shaw was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 21Full year 2025 earnings released: AU$0.04 loss per share (vs AU$0 in FY 2024)Full year 2025 results: AU$0.04 loss per share (further deteriorated from AU$0 in FY 2024). Revenue: AU$7.53m (down 7.0% from FY 2024). Net loss: AU$264.0k (down 378% from profit in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 186 percentage points per year, which is a significant difference in performance.お知らせ • Aug 13PharmX Technologies Limited to Report Fiscal Year 2025 Results on Aug 20, 2025PharmX Technologies Limited announced that they will report fiscal year 2025 results on Aug 20, 2025お知らせ • Feb 03PharmX Technologies Limited to Report First Half, 2025 Results on Feb 19, 2025PharmX Technologies Limited announced that they will report first half, 2025 results on Feb 19, 2025お知らせ • Nov 28PharmX Technologies Limited Announces Change of Company SecretaryPharmX Technologies Limited announced the appointment of Christopher Fernandes as Company Secretary with effect from 27 November 2024, replacing Sally McDow. Mr. Fernandes is an employee of BoardRoom Pty Ltd. (the Company's Corporate Secretarial provider). Chris is an experienced Company Secretary with expertise in corporate governance functions of private and public companies in both Australia and the United Kingdom. For the purpose of ASX listing rule 12.6, Mr. Fernandes will be the person responsible for communications with the ASX in relation to ASX Listing Rule matters.お知らせ • Oct 25PharmX Technologies Limited, Annual General Meeting, Nov 26, 2024PharmX Technologies Limited, Annual General Meeting, Nov 26, 2024. Location: bdo audit pty ltd at rooms 5 & 6, level 11, 1 margaret street, sydney nsw 2000, sydney Australiaお知らせ • Sep 11PharmX Technologies Limited Appoints Alexander Mellis as A Non-Executive and Independent Alternate DirectorPharmX Technologies Ltd. has announced a change to its Board of Directors, appointing Alexander (Sandy) Mellis as a Non-Executive and Independent Alternate Director for Mr. Dennis Bastas, effective immediately. Sandy Mellis brings over 25 years of experience in the consumer health and goods sectors, having developed and managed brands across Australia, New Zealand, the UK, the US, and Europe. His recent roles include serving as Chief Commercial Officer of DBG Health and Chief Executive Officer of VidaCorp, the Consumer Health & Beauty division of DBG Health.Reported Earnings • Aug 28Full year 2024 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2023)Full year 2024 results: EPS: AU$0 (improved from AU$0.001 loss in FY 2023). Revenue: AU$8.09m (up 32% from FY 2023). Net income: AU$95.0k (up AU$978.0k from FY 2023). Profit margin: 1.2% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings.お知らせ • Jul 24PharmX Technologies Limited to Report Fiscal Year 2024 Results on Aug 21, 2024PharmX Technologies Limited announced that they will report fiscal year 2024 results on Aug 21, 2024Board Change • May 02Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Non-Executive Director Jayne Shaw was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Mar 07Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Non-Executive Director Jayne Shaw was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Feb 24First half 2024 earnings released: EPS: AU$0 (vs AU$0.001 loss in 1H 2023)First half 2024 results: EPS: AU$0 (improved from AU$0.001 loss in 1H 2023). Revenue: AU$3.24m (down 47% from 1H 2023). Net income: AU$236.0k (up AU$807.0k from 1H 2023). Profit margin: 7.3% (up from net loss in 1H 2023). The move to profitability was driven by lower expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Software industry in Australia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.お知らせ • Feb 14PharmX Technologies Limited to Report First Half, 2024 Results on Feb 23, 2024PharmX Technologies Limited announced that they will report first half, 2024 results on Feb 23, 2024New Risk • Feb 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$15.0m (US$9.76m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 7.1% per year for the foreseeable future. Market cap is less than US$10m (AU$15.0m market cap, or US$9.76m). Minor Risk Revenue is less than US$5m (AU$6.1m revenue, or US$4.0m).Board Change • Jan 25Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Non-Executive Director Jayne Shaw was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Nov 17PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023The Board of PharmX Technologies Limited announced the appointment of Tom Culver as CEO effective 20th November 2023. Tom joins PharmX with an extensive background in leading innovative technology companies, driving sales and implementing growth strategies. He has over 20 years of experience as a founder and business owner, as well as in senior leadership roles in organizations across the public and private sectors in both B2B and consumer focused enterprises. His appointment comes as PharmX is poised for growth following significant recent investment in its EDI gateway and Marketplace capabilities. His technology, growth and leadership experience will be vital as the company focuses on revenue growth, delivering exceptional customer engagement, and raising its profile with enterprise providers and pharmacists across Australia and New Zealand. Nick England will revert to his role as non-executive Chairman after a brief transition period.お知らせ • Oct 20PharmX Technologies Limited, Annual General Meeting, Nov 21, 2023PharmX Technologies Limited, Annual General Meeting, Nov 21, 2023, at 11:01 AUS Eastern Standard Time. Location: Suite 11.02, Level 11, 17 Castlereagh Street Sydney New South Wales Australia Agenda: To consider and approve the Financial Statements, Directors' Report and Auditor's Report of the Company for the year ended 30 June 2023; to consider and approve election of Directors; to consider and approve remuneration report; to consider and approve of Additional 10% Placement Facility.Board Change • Sep 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Dennis Bastas was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Sep 01New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 7.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 7.1% per year for the foreseeable future. Minor Risks Revenue is less than US$5m (AU$6.1m revenue, or US$3.9m). Market cap is less than US$100m (AU$23.9m market cap, or US$15.4m).Reported Earnings • Aug 24Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0 in FY 2022)Full year 2023 results: AU$0.002 loss per share (further deteriorated from AU$0 in FY 2022). Revenue: AU$6.13m (down 49% from FY 2022). Net loss: AU$883.0k (down AU$901.0k from profit in FY 2022). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Software industry in Australia.お知らせ • Aug 18Corum Group Limited to Report Fiscal Year 2023 Results on Aug 23, 2023Corum Group Limited announced that they will report fiscal year 2023 results on Aug 23, 2023Board Change • Aug 15No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Dennis Bastas was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jul 23Jonas Software AUS Pty Ltd entered into an agreement to acquire Corum Health Pty Ltd and Amfac Pty Ltd. from Corum Group Limited (ASX:COO) for AUD 6.3 million.Jonas Software AUS Pty Ltd entered into an agreement to acquire Corum Health Pty Ltd and Amfac Pty Ltd. from Corum Group Limited (ASX:COO) for AUD 6.3 million on July 21, 2023. The purchase price of AUD 6.25 million, on a cash free and debt free basis and subject to working capital adjustments, comprises of an initial purchase amount of AUD 4.75 million and a deferred purchase amount of AUD 1.5 million (payable on the first anniversary of completion, subject to any price adjustment for working capital adjustments or warranty claims). The purchase price may be increased through the achievement of annual recurring revenue targets (earnout payments) based on the achievement of certain business metrics on the first and second anniversaries of completion. Completion of the sale is subject to shareholder approval.Buying Opportunity • Jul 10Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be AU$0.048, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.0% over the last 3 years. Meanwhile, the company became loss making.Board Change • Apr 14No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Dennis Bastas was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Mar 07No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Dennis Bastas was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jan 06No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Dennis Bastas was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Dec 07No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Dennis Bastas was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Dennis Bastas was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Oct 25No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Interim CEO & Executive Chairman Nick England is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Reported Earnings • Aug 31Full year 2022 earnings released: EPS: AU$0 (vs AU$0.002 in FY 2021)Full year 2022 results: EPS: AU$0 (down from AU$0.002 in FY 2021). Revenue: AU$12.0m (down 11% from FY 2021). Net income: AU$18.0k (down 98% from FY 2021). Profit margin: 0.2% (down from 8.2% in FY 2021). The decrease in margin was driven by lower revenue.Board Change • Jul 23No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Interim CEO & Executive Chairman Nick England is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Board Change • Jun 08No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Interim CEO & Executive Chairman Nick England is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Board Change • May 17No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Interim CEO & Executive Chairman Nick England is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Board Change • Apr 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Interim CEO & Executive Chairman Nick England is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Board Change • Mar 15No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Interim CEO & Executive Chairman Nick England is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Reported Earnings • Feb 12First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: EPS: AU$0 (down from AU$0.002 in 1H 2021). Revenue: AU$6.10m (up 4.1% from 1H 2021). Net income: AU$88.0k (down 91% from 1H 2021). Profit margin: 1.4% (down from 17% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 5.6%. Earnings per share (EPS) were in line with analyst estimates. Over the next year, revenue is forecast to grow 10%, compared to a 32% growth forecast for the industry in Australia. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth.Board Change • Oct 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Group Chairman of the Board Nick England is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Aug 22Full year 2021 earnings released: EPS AU$0.002 (vs AU$0.001 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$13.4m (up 26% from FY 2020). Net income: AU$1.09m (up AU$915.0k from FY 2020). Profit margin: 8.2% (up from 1.7% in FY 2020). Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth.Reported Earnings • Feb 26First half 2021 earnings released: EPS AU$0.002 (vs AU$0.001 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: AU$6.64m (up 33% from 1H 2020). Net income: AU$988.0k (up AU$1.29m from 1H 2020). Profit margin: 15% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.株主還元PHXAU SoftwareAU 市場7D-4.3%-0.9%0.08%1Y37.5%-48.2%3.1%株主還元を見る業界別リターン: PHX過去 1 年間で-48.2 % の収益を上げたAustralian Software業界を上回りました。リターン対市場: PHX過去 1 年間で3.1 % の収益を上げたAustralian市場を上回りました。価格変動Is PHX's price volatile compared to industry and market?PHX volatilityPHX Average Weekly Movement14.1%Software Industry Average Movement11.2%Market Average Movement10.4%10% most volatile stocks in AU Market17.6%10% least volatile stocks in AU Market4.3%安定した株価: PHXの株価は、 Australian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: PHXの weekly volatility ( 14% ) は過去 1 年間安定していますが、依然としてAustralianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1950n/aTom Culverpharmx.com.auファーマックス・テクノロジーズ社は、その子会社とともにオーストラリアでテクノロジーおよびソフトウェア開発会社として事業を展開している。また、電子注文ゲートウェイのPharmX、オンライン販売・マーケティングプラットフォームのPharmX Marketplace、サプライヤーや薬局の顧客の業務に関する洞察を提供するPharmX Analyticsを運営している。前身はCorum Group Limitedで、2023年10月にPharmX Technologies Limitedに社名変更。ファーマックス・テクノロジーズ・リミテッドは1950年に設立され、オーストラリアのシドニーに本社を置いている。もっと見るPharmX Technologies Limited 基礎のまとめPharmX Technologies の収益と売上を時価総額と比較するとどうか。PHX 基礎統計学時価総額AU$72.54m収益（TTM）-AU$931.00k売上高(TTM)AU$7.65m9.5xP/Sレシオ-77.9xPER（株価収益率PHX は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PHX 損益計算書（TTM）収益AU$7.65m売上原価AU$5.91m売上総利益AU$1.73mその他の費用AU$2.66m収益-AU$931.00k直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.0014グロス・マージン22.66%純利益率-12.17%有利子負債／自己資本比率0%PHX の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 09:22終値2026/05/21 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PharmX Technologies Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Caleb WengPAC Partners Securities Pty. Ltd.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Jayne Shaw was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 53% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (AU$75.8m market cap, or US$55.2m).
Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Jayne Shaw was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 04PharmX Technologies Limited to Report First Half, 2026 Results on Feb 25, 2026PharmX Technologies Limited announced that they will report first half, 2026 results on Feb 25, 2026
Board Change • Dec 24Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Jayne Shaw was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 13PharmX Technologies Limited, Annual General Meeting, Nov 11, 2025PharmX Technologies Limited, Annual General Meeting, Nov 11, 2025.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Jayne Shaw was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 53% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (AU$75.8m market cap, or US$55.2m).
Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Jayne Shaw was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 04PharmX Technologies Limited to Report First Half, 2026 Results on Feb 25, 2026PharmX Technologies Limited announced that they will report first half, 2026 results on Feb 25, 2026
Board Change • Dec 24Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Jayne Shaw was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 13PharmX Technologies Limited, Annual General Meeting, Nov 11, 2025PharmX Technologies Limited, Annual General Meeting, Nov 11, 2025.
お知らせ • Sep 01Pharmx Technologies Limited Announces Board Changes, Effective 1 September 2025PharmX Technologies Limited announced that Mr. Alexander (Sandy) Mellis has been appointed as a full Non-Executive Director of the Company with effect from1 September 2025, having resigned from his position as an Alternate Director to Mr. Dennis Bastas. Mr. Mellis has acted as an Alternate Director to Mr. Bastas since September 2024 and has provided invaluable contribution to the Board during this time. Mr. Mellis will continue to provide his 25+ years industry experience in consumer health brands and the Australian consumer goods market across a variety of market channels to the Company, having consented to a full position on the Board. Mr. Mellis has been appointed to fill a casual vacancy in accordance with the Company's Constitution until the Company's 2025 Annual General Meeting (AGM) whereby Mr. Mellis will stand for election in accordance with the Company's Constitution and ASX Listing Rules. The Company notes it was originally intended that Mr. Mellis remain as Alternate Director until the 2025 AGM where he was then due to step down as an Alternate Director and stand for election as a Non-Executive Director, however the Board (with Mr. Mellis' endorsement) has chosen to expedite the appoint of Mr. Mellis in light of the immediate resignation of Mr. Dennis Bastas. The Company has identified and acknowledges a breach of ASX Listing Rule 14.4 in relation to Mr. Bastas' current term as a Director of the Company. At the 2024 AGM, Pharmx had planned to seek re-election of Mr. Bastas as a Non-Executive Director in accordance with the requirements under its Constitution and the ASX's Listing Rules, however due to an administrative oversight from its 2024 AGM the resolution was omitted from the Notice of Meeting, resulting in Mr. Bastas continuing as a Director for a period longer than the 3-year term stipulated by the ASX Listing Rules without standing for re- election. Mr. Bastas, by mutual agreement with the Company, has resigned as a Director of the Company with effective from 1 September 2025, allowing him to focus more fully on his position as Chairman & Group CEO of DBG Health.
Board Change • Aug 23Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Jayne Shaw was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 21Full year 2025 earnings released: AU$0.04 loss per share (vs AU$0 in FY 2024)Full year 2025 results: AU$0.04 loss per share (further deteriorated from AU$0 in FY 2024). Revenue: AU$7.53m (down 7.0% from FY 2024). Net loss: AU$264.0k (down 378% from profit in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 186 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 13PharmX Technologies Limited to Report Fiscal Year 2025 Results on Aug 20, 2025PharmX Technologies Limited announced that they will report fiscal year 2025 results on Aug 20, 2025
お知らせ • Feb 03PharmX Technologies Limited to Report First Half, 2025 Results on Feb 19, 2025PharmX Technologies Limited announced that they will report first half, 2025 results on Feb 19, 2025
お知らせ • Nov 28PharmX Technologies Limited Announces Change of Company SecretaryPharmX Technologies Limited announced the appointment of Christopher Fernandes as Company Secretary with effect from 27 November 2024, replacing Sally McDow. Mr. Fernandes is an employee of BoardRoom Pty Ltd. (the Company's Corporate Secretarial provider). Chris is an experienced Company Secretary with expertise in corporate governance functions of private and public companies in both Australia and the United Kingdom. For the purpose of ASX listing rule 12.6, Mr. Fernandes will be the person responsible for communications with the ASX in relation to ASX Listing Rule matters.
お知らせ • Oct 25PharmX Technologies Limited, Annual General Meeting, Nov 26, 2024PharmX Technologies Limited, Annual General Meeting, Nov 26, 2024. Location: bdo audit pty ltd at rooms 5 & 6, level 11, 1 margaret street, sydney nsw 2000, sydney Australia
お知らせ • Sep 11PharmX Technologies Limited Appoints Alexander Mellis as A Non-Executive and Independent Alternate DirectorPharmX Technologies Ltd. has announced a change to its Board of Directors, appointing Alexander (Sandy) Mellis as a Non-Executive and Independent Alternate Director for Mr. Dennis Bastas, effective immediately. Sandy Mellis brings over 25 years of experience in the consumer health and goods sectors, having developed and managed brands across Australia, New Zealand, the UK, the US, and Europe. His recent roles include serving as Chief Commercial Officer of DBG Health and Chief Executive Officer of VidaCorp, the Consumer Health & Beauty division of DBG Health.
Reported Earnings • Aug 28Full year 2024 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2023)Full year 2024 results: EPS: AU$0 (improved from AU$0.001 loss in FY 2023). Revenue: AU$8.09m (up 32% from FY 2023). Net income: AU$95.0k (up AU$978.0k from FY 2023). Profit margin: 1.2% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings.
お知らせ • Jul 24PharmX Technologies Limited to Report Fiscal Year 2024 Results on Aug 21, 2024PharmX Technologies Limited announced that they will report fiscal year 2024 results on Aug 21, 2024
Board Change • May 02Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Non-Executive Director Jayne Shaw was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Mar 07Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Non-Executive Director Jayne Shaw was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Feb 24First half 2024 earnings released: EPS: AU$0 (vs AU$0.001 loss in 1H 2023)First half 2024 results: EPS: AU$0 (improved from AU$0.001 loss in 1H 2023). Revenue: AU$3.24m (down 47% from 1H 2023). Net income: AU$236.0k (up AU$807.0k from 1H 2023). Profit margin: 7.3% (up from net loss in 1H 2023). The move to profitability was driven by lower expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Software industry in Australia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 14PharmX Technologies Limited to Report First Half, 2024 Results on Feb 23, 2024PharmX Technologies Limited announced that they will report first half, 2024 results on Feb 23, 2024
New Risk • Feb 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$15.0m (US$9.76m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 7.1% per year for the foreseeable future. Market cap is less than US$10m (AU$15.0m market cap, or US$9.76m). Minor Risk Revenue is less than US$5m (AU$6.1m revenue, or US$4.0m).
Board Change • Jan 25Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Non-Executive Director Jayne Shaw was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Nov 17PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023The Board of PharmX Technologies Limited announced the appointment of Tom Culver as CEO effective 20th November 2023. Tom joins PharmX with an extensive background in leading innovative technology companies, driving sales and implementing growth strategies. He has over 20 years of experience as a founder and business owner, as well as in senior leadership roles in organizations across the public and private sectors in both B2B and consumer focused enterprises. His appointment comes as PharmX is poised for growth following significant recent investment in its EDI gateway and Marketplace capabilities. His technology, growth and leadership experience will be vital as the company focuses on revenue growth, delivering exceptional customer engagement, and raising its profile with enterprise providers and pharmacists across Australia and New Zealand. Nick England will revert to his role as non-executive Chairman after a brief transition period.
お知らせ • Oct 20PharmX Technologies Limited, Annual General Meeting, Nov 21, 2023PharmX Technologies Limited, Annual General Meeting, Nov 21, 2023, at 11:01 AUS Eastern Standard Time. Location: Suite 11.02, Level 11, 17 Castlereagh Street Sydney New South Wales Australia Agenda: To consider and approve the Financial Statements, Directors' Report and Auditor's Report of the Company for the year ended 30 June 2023; to consider and approve election of Directors; to consider and approve remuneration report; to consider and approve of Additional 10% Placement Facility.
Board Change • Sep 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Dennis Bastas was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Sep 01New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 7.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 7.1% per year for the foreseeable future. Minor Risks Revenue is less than US$5m (AU$6.1m revenue, or US$3.9m). Market cap is less than US$100m (AU$23.9m market cap, or US$15.4m).
Reported Earnings • Aug 24Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0 in FY 2022)Full year 2023 results: AU$0.002 loss per share (further deteriorated from AU$0 in FY 2022). Revenue: AU$6.13m (down 49% from FY 2022). Net loss: AU$883.0k (down AU$901.0k from profit in FY 2022). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Software industry in Australia.
お知らせ • Aug 18Corum Group Limited to Report Fiscal Year 2023 Results on Aug 23, 2023Corum Group Limited announced that they will report fiscal year 2023 results on Aug 23, 2023
Board Change • Aug 15No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Dennis Bastas was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 23Jonas Software AUS Pty Ltd entered into an agreement to acquire Corum Health Pty Ltd and Amfac Pty Ltd. from Corum Group Limited (ASX:COO) for AUD 6.3 million.Jonas Software AUS Pty Ltd entered into an agreement to acquire Corum Health Pty Ltd and Amfac Pty Ltd. from Corum Group Limited (ASX:COO) for AUD 6.3 million on July 21, 2023. The purchase price of AUD 6.25 million, on a cash free and debt free basis and subject to working capital adjustments, comprises of an initial purchase amount of AUD 4.75 million and a deferred purchase amount of AUD 1.5 million (payable on the first anniversary of completion, subject to any price adjustment for working capital adjustments or warranty claims). The purchase price may be increased through the achievement of annual recurring revenue targets (earnout payments) based on the achievement of certain business metrics on the first and second anniversaries of completion. Completion of the sale is subject to shareholder approval.
Buying Opportunity • Jul 10Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be AU$0.048, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.0% over the last 3 years. Meanwhile, the company became loss making.
Board Change • Apr 14No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Dennis Bastas was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Mar 07No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Dennis Bastas was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jan 06No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Dennis Bastas was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Dec 07No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Dennis Bastas was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Dennis Bastas was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Oct 25No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Interim CEO & Executive Chairman Nick England is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Reported Earnings • Aug 31Full year 2022 earnings released: EPS: AU$0 (vs AU$0.002 in FY 2021)Full year 2022 results: EPS: AU$0 (down from AU$0.002 in FY 2021). Revenue: AU$12.0m (down 11% from FY 2021). Net income: AU$18.0k (down 98% from FY 2021). Profit margin: 0.2% (down from 8.2% in FY 2021). The decrease in margin was driven by lower revenue.
Board Change • Jul 23No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Interim CEO & Executive Chairman Nick England is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Board Change • Jun 08No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Interim CEO & Executive Chairman Nick England is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Board Change • May 17No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Interim CEO & Executive Chairman Nick England is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Board Change • Apr 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Interim CEO & Executive Chairman Nick England is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Board Change • Mar 15No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Interim CEO & Executive Chairman Nick England is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Reported Earnings • Feb 12First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: EPS: AU$0 (down from AU$0.002 in 1H 2021). Revenue: AU$6.10m (up 4.1% from 1H 2021). Net income: AU$88.0k (down 91% from 1H 2021). Profit margin: 1.4% (down from 17% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 5.6%. Earnings per share (EPS) were in line with analyst estimates. Over the next year, revenue is forecast to grow 10%, compared to a 32% growth forecast for the industry in Australia. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth.
Board Change • Oct 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Group Chairman of the Board Nick England is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Aug 22Full year 2021 earnings released: EPS AU$0.002 (vs AU$0.001 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$13.4m (up 26% from FY 2020). Net income: AU$1.09m (up AU$915.0k from FY 2020). Profit margin: 8.2% (up from 1.7% in FY 2020). Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Feb 26First half 2021 earnings released: EPS AU$0.002 (vs AU$0.001 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: AU$6.64m (up 33% from 1H 2020). Net income: AU$988.0k (up AU$1.29m from 1H 2020). Profit margin: 15% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.
